Medical Doctor Program year 2022 Reported 2020–2022 Source: CMS Open Payments, 2026 publication

Priyanka Tiwari

Gastroenterology Saint Louis, MO Medical Doctor

NPI 1295837441 CMS profile 569807

615 S New Ballas Rd Ste 1200, Saint Louis, MO 63141

Open in the dashboard

General payments

$2,208

133 records reported · program years 2020–2022

Research payments

$0

Paid to them · None reported · program years 2020–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Priyanka Tiwari of Saint Louis, MO is reported in the CMS Open Payments database as having received $2,208 across 133 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $829 46
2021 General $722 45
2020 General $657 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Priyanka Tiwari
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Priyanka Tiwari were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Priyanka Tiwari Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $657 $224 $74–$624 $114
2021 $722 $352 $106–$1,054 $132
2022 $829 $448 $129–$1,270 $149
2023 $0 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2020–2022
  1. AbbVie, Inc. $538 30 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $160 10 payments
  3. Gilead Sciences, Inc. $157 9 payments
  4. Novo Nordisk Inc $149 9 payments
  5. Genzyme Corporation $91 5 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $90 6 payments
  7. Dexcom, Inc. $73 5 payments
  8. Amarin Pharma Inc. $71 5 payments
  9. SK Life Science, Inc. $67 4 payments
  10. Braintree Laboratories, Inc. $62 4 payments
  11. Other $751 46 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2022
  1. Food and Beverage $2,208 133 payments
Products named General payments · program years 2020–2022
  1. JARDIANCE $160 10 payments
  2. Ozempic $149 9 payments
  3. RYBELSUS $149 9 payments
  4. MAVYRET $144 9 payments
  5. HUMIRA $105 4 payments
  6. LINZESS $98 8 payments
  7. AUBAGIO $91 5 payments
  8. CREON $85 7 payments
  9. Vascepa $71 5 payments
  10. XIFAXAN $65 4 payments
  11. Other $1,277 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

275

Median for Gastroenterology: 569

Drug cost

$4,135

Median for Gastroenterology: $104,976

Branded share of claims

57.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 82 $1,248
Omeprazole Generic 67 $1,062
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 24 $390
Loperamide Loperamide Hcl Brand 24 $302
Ondansetron Hcl Generic 12 $292
Ondansetron Odt Ondansetron Brand 14 $271
Dicyclomine Hcl Generic 22 $249
Famotidine Generic 16 $180
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 14 $142

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$17,565

Medicare's payments for the services billed

Medicare patients

105

Average age 71

Services billed

170

62 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 49%
Chronic kidney disease 27%
Ischemic heart disease 26%
Diabetes 23%
Heart failure 20%
Depression 20%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record